Page last updated: 2024-10-25

eflornithine and Deafness, Transitory

eflornithine has been researched along with Deafness, Transitory in 6 studies

Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.

Research Excerpts

ExcerptRelevanceReference
"A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos."5.13Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. ( Chen, WP; Fujikawa-Brooks, S; Gerner, EW; Gillen, DL; McLaren, CE; Meyskens, FL; Pelot, D, 2008)
"Recent clinical cancer chemoprevention trials, using dose de-escalation designs, indicate that DFMO can be given over long periods of time at low doses that suppress polyamine contents in gastrointestinal and other epithelial tissues but cause no detectable hearing loss or other side effects."2.40Development of difluoromethylornithine (DFMO) as a chemoprevention agent. ( Gerner, EW; Meyskens, FL, 1999)
"Reversible hearing loss is a recognized toxicity of DFMO that usually occurs at doses above 2 g/m(2)/d, and generally when the cumulative dose exceeds 250 g/m(2)."1.32Irreversible ototoxicity associated with difluoromethylornithine. ( Backoff, P; Brenner, DE; Eaton, T; Hawk, ET; Lao, CD; McCarty, D; Ondrey, FG; Shotland, LI; Spechler, SJ; Viner, JL, 2004)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Chow, CL1
Havighurst, T1
Lozar, T1
Jones, TD1
Kim, K1
Bailey, HH1
Lewis, JR1
O'Brien, TG1
Skorupski, KA1
Krick, EL1
Reiter, AM1
Jennings, MW1
Jurney, CH1
Shofer, FS1
Kim, DJ1
Roh, E1
Lee, MH1
Oi, N1
Lim, DY1
Kim, MO1
Cho, YY1
Pugliese, A1
Shim, JH1
Chen, H1
Cho, EJ1
Kim, JE1
Kang, SC1
Paul, S1
Kang, HE1
Jung, JW1
Lee, SY1
Kim, SH1
Reddy, K1
Yeom, YI1
Bode, AM1
Dong, Z1
McLaren, CE1
Fujikawa-Brooks, S1
Chen, WP1
Gillen, DL1
Pelot, D1
Gerner, EW2
Meyskens, FL2
Lao, CD1
Backoff, P1
Shotland, LI1
McCarty, D1
Eaton, T1
Ondrey, FG1
Viner, JL1
Spechler, SJ1
Hawk, ET1
Brenner, DE1

Reviews

1 review available for eflornithine and Deafness, Transitory

ArticleYear
Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cell Division; Cell Trans

1999

Trials

2 trials available for eflornithine and Deafness, Transitory

ArticleYear
Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
    The Laryngoscope, 2023, Volume: 133, Issue:3

    Topics: Eflornithine; Hearing; Hearing Loss; Humans; Ototoxicity; Skin Neoplasms

2023
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
    Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:7

    Topics: Adenomatous Polyps; Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Colonic N

2008

Other Studies

3 other studies available for eflornithine and Deafness, Transitory

ArticleYear
Polyamine inhibitors for treatment of feline oral squamous cell carcinoma: a proof-of-concept study.
    Journal of veterinary dentistry, 2013,Fall, Volume: 30, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Eflornithine; Evoked P

2013
Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity.
    Cancer research, 2016, 03-01, Volume: 76, Issue:5

    Topics: Allosteric Regulation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; An

2016
Irreversible ototoxicity associated with difluoromethylornithine.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2004, Volume: 13, Issue:7

    Topics: Antineoplastic Agents; Barrett Esophagus; Cell Proliferation; Chemoprevention; Eflornithine; Hearing

2004